Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2015, Pages 1840-1848

  Leung, Kelvin C W ^a   Pannu, Neesh ^c   Tan, Zhi ^b   Ghali, William A ^a,b   Knudtson, Merril L ^a   Hemmelgarn, Brenda R ^a,b   Tonelli, Marcello ^a   James, Matthew T ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; CONTRAST MEDIUM; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; AGED; ALBUMINURIA; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CLINICAL PRACTICE; COMPLICATION; FEMALE; GLOMERULUS FILTRATION RATE; MALE; PATHOPHYSIOLOGY; PRESCRIPTION; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY INJURY; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84926443905     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03460414     Document Type: Article

References (45)

1. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone G W, Leon M B, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 44: 1393–1399, 2004.
2. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93: 1515–1519, 2004.
3. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM: Longterm prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 168: 987–995, 2008.
4. Coca SGS, Yusuf B, Shlipak MGM, Garg AXA, Parikh CR: Long term risk of mortality and other adverse outcomes after acute kidney injury: A systematic review and meta-analysis. Am J Kidney Dis 53: 961–973, 2009.
5. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, Manns BJ, Klarenbach SW, Hemmelgarn BR; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators: Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123: 409–416, 2011.
6. Guitterez NV, Diaz A, Timmis GC, O’Neill WW, Stevens MA, Sandberg KR, McCullough PA: Determinants of serumcreatinine trajectory in acute contrast nephropathy. J Interv Cardiol 15: 349–354, 2002.
7. Arnold JMO, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, Lonn E, Pogue J, Bosch J; HOPE Investigators: Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107: 1284–1290, 2003.
8. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302, 1991.
9. Swedberg K, Kjekshus J: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62: 60A–66A, 1988.
10. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435, 1987.
11. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr., Kastelein JJP, Koenig W, Libby P, Lorenzatti A J, MacFadyen J G, Nordestgaard B G, Shepherd J, Willerson J T, Glynn RJ; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207, 2008.
12. Ridker PM, MacFadyen J, Cressman M, Glynn RJ: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial EvaluatingRosuvastatin) trial. J AmColl Cardiol 55: 1266–1273, 2010.
13. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J: Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol 1: 796–801, 2006.
14. Winkelmayer WC, Levin R, Setoguchi S: Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol 3: 1415–1422, 2008.
15. Winkelmayer WC, Bucsics AE, Schautzer A, Wieninger P, Pogantsch M; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds:Use of recommendedmedications aftermyocardial infarction in Austria. Eur J Epidemiol 23: 153–162, 2008.
16. Chang TI, Desai M, Solomon DH, Winkelmayer WC: Kidney function and long-term medication adherence after myocardial infarction in the elderly. Clin JAmSocNephrol 6: 864–869, 2011.
17. Winkelmayer WC, Charytan DM, Levin R, Avorn J: Poor short term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 47: 301–308, 2006.
18. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160: 685–693, 2000.
19. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA: Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115: 513–519, 1991.
20. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553, 2008.
21. Ghali WA, Knudtson ML: Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators. Can J Cardiol 16: 1225–1230, 2000.
22. Clement FM, James MT, Chin R, Klarenbach SW, Manns BJ, Quinn RR, Ravani P, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network: Validation of a case definition to define chronic dialysis using outpatient administrative data. BMC Med Res Methodol 11: 25, 2011.
23. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M: Overview of the Alberta Kidney Disease Network. BMC Nephrol 10: 30, 2009.
24. Levey A S, Stevens L A, Schmid C H, Zhang Y L, Castro A F 3rd, Feldman HI, Kusek J W, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int 2: 19–36, 2012.
26. Lamb EJ, MacKenzie F, Stevens PE: How should proteinuria be detected and measured? Ann Clin Biochem 46: 205–217, 2009.
27. R Core Team (2013). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.r-project.org. Accessed August 28, 2014.
28. Balasubramanian G, Al-Aly Z, Moiz A, Rauchman M, Zhang Z, Gopalakrishnan R, Balasubramanian S, El-Achkar TM: Early nephrologist involvement in hospital-acquired acute kidney injury: A pilot study. Am J Kidney Dis 57: 228–234, 2011.
29. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, Lohr J: Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 3: 1266–1273, 2008.
30. Wright JT Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421–2431, 2002.
31. Testani JM, Kimmel SE, Dries DL, Coca SG: Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4: 685–691, 2011.
32. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863, 1997.
33. Keane WF, Brenner BM, de Zeeuw D, Grunfeld J-P, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499–1507, 2003.
34. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvar1Qo F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JBL, Mangili R, Moore J Jr., Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rod by RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J AmSoc Nephrol 16: 3027–3037, 2005.
35. Pfeffer MA, Braunwald E, Moye´ LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM: Effect of captopril on mortality andmorbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669–77, 1992.
36. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559, 2008.
37. Zhang B-C, Li W-M, Xu Y-W: High-dose statin pretreatment for the prevention of contrast-induced nephropathy: A meta-analysis. Can J Cardiol 27: 851–858, 2011.
38. Argalious MY, Dalton JE, Cywinski JB, Seif J, Abdelmalak M, Sessler DI: Association between preoperative statin therapy and postoperative change in glomerular filtration rate in endovascular aortic surgery. Br J Anaesth 109: 161–167, 2012.
39. Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD: Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton) 15: 165–170, 2010.
40. Mithani S, Kuskowski M, Slinin Y, Ishani A, McFalls E, Adabag S: Dose-dependent effect of statins on the incidence of acute kidney injury after cardiac surgery. Ann Thorac Surg 91: 520–525, 2011.
41. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS: Effect of statin therapy on contrast-induced nephropathy after coronary angiography: A meta-analysis. Int J Cardiol 151: 348–353, 2011.
42. Li Y, Liu Y, Fu L, Mei C, Dai B: Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: A metaanalysis of seven randomized controlled trials. PLoS ONE 7: e34450, 2012.
43. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, Ding S, Jia S, Shen W, Wang D, Sun L, Qiu J, Wang X, Li Y, Deng J, Li J, Xu K, Xu B, Mehran R, Huo Y: Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63: 62–70, 2014.
44. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F: Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J AmColl Cardiol 63: 71–79, 2014.
45. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance J-P, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies: Use of high potency statins and rates of admission for acute kidney injury: Multicenter, retrospective observational analysis of administrative databases. BMJ 346: f880, 2013.